ANALYSIS OF DYSLIPIDEMIA AMONG HEMODIALYSIS PATIENTS A CROSS SECTIONAL STUDY

Chronic kidney disease (CKD) is a major health burden that has a high morbidity and death rate and is steadily becoming more common. Worldwide, there are about 2. 6 million individuals receiving dialysis. Cardiovascular mortality is 10-20 times higher in patients on dialysis and accounting for over 50% of fatalities in this population than in the general population. Many studies have shown that patients on haemodialysis have elevated triglyceride and low HDL, these contribute to an increase in atherosclerotic risk. An independent risk factor and the primary cause of death for Individuals who undergoes dialysis, according to registry studies is cardiovascular disease (CVD) The patients undergoing haemodialysis have increased levels of atherogenic lipoprotein than non- uremic patients. Alteration in the lipoprotein levels in patients with hemodialysis will lead to atherosclerosis. The presence of CKD and diabetes with CVD have additive effects of worsening each other conditions, leading to an increase in morbidity and mortality.

Owing to the risk of Cardiovascular complications associated with CKD detection of dyslipidemia is important and prompt initiation of treatment with novel forms of therapy to manage blood pressure, dyslipidemia, and glucose levels is crucial. According to the KDIGO Guideline, in the general population, the treatment of dyslipidaemia is more rigorous but in CKD patients, the management is relatively. conservative regarding the diagnosis and treating with lipid lowering agents. Despite this recommendation, lipid levels are not assessed in CKD patients, this has largely attributed to lack of the high-quality evidence among the CKD patients and the overall feature of dyslipidaemia is considerably distinctive to that of the general population. Studies have shown that Lipid-lowering agents, can provide significant benefits for hemodialysis patients. Studies indicate a 25% reduction in mortality risk and a 12% decrease in major adverse cardiovascular events (MACES) among those using anti-dyslipidemia agents compared to non-users thus, there is limited information on dyslipidaemia among dialysis populations. In our study, we focus to determine the proportion of dyslipidemia and estimate mortality risk rate in HD patients. To compare lipid profile and determine the risk factors associated with the HD patients with T2DM and HD with non-T2DM patients.